The leading companies operating in the anti-snoring devices and snoring surgery market have been focusing on product innovation and miniaturization of sleep apnea devices. This is a novel trend swaying the global anti-snoring devices and snoring surgery market. Integrated by the nanotechnology, this trend could be a major determinant for the market’s growth. Currently, the market is exhibiting a strong focus on innovation, as per a new study by Transparency Market Research. Efforts by new and existing players have resulted in the development of an impressive pipeline of products that are expected to help find better cure for people suffering from sleep apnea.
Q: What strategies are the leading market players adopting to gain stronghold?
A: The global anti-snoring devices and snoring surgery market is marked by the presence of an increasing number of companies which has rendered its vendor landscape highly competitive and fragmented. TMR finds that enterprises such as Medtronic plc, Philips Healthcare, GE Healthcare, Fisher & Paykel Healthcare, and ResMed, Inc are not only leading market participant but also hold significant share in the global market with their robust geographic reach and extensive product portfolio.
Of these, Medtronic has managed emerging dominant in the overall market following a slew of recent acquisitions. Medtronic along with Phillips Healthcare and GE healthcare are the top players in the market, contributing a whopping 93.69% of the overall revenue generated by the market. In order to accelerate their pace of gains, a majority of the leading companies operating in the anti-snoring devices and snoring surgery market are investing in research and development activities.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6910
Besides this they are also focusing on product innovation to strengthen their position in the market. For instance, an Australian company has recently launched a 3D printed anti-snoring device that can be customized based on an individual’s need. The medical device company is called Oventus Medical and is based in Melbourne, Australia. It is set to manufacture a device they named O2Vent. It is a lightweight titanium devices and can help patients stop snoring by delivering air to the back of his or her mouth. Such innovations hold great promise of the company success in the market
Q: Which region will offer most lucrative opportunities to the market?
A: North America and Europe together dominated the global anti-soring devices and snoring surgery market in 2015. While these are mature markets, the opportunities existing in Asia Pacific is also expected to prove quite lucrative for companies manufacturing anti-snoring devices. Because the region is characterized by presence of unmet medical needs and high patient pool it is expected to attract several of the small or medium scale companies and new entrants looking to establish their footprint in the market. In addition favorable government initiatives to spread awareness about sleep apnea and its possible treatments will also support the market’s strong growth in Asia Pacific.
Cone Beam Computed Tomography Market Dynamics and Opportunities Report by Transparency Market Research
According to a new market report published by Transparency Market Research “Cone Beam Computed Tomography (CBCT) Market (Application – Dental Implants, Orthodontics, Oral Surgery, Endodontics, and General Surgery): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2015–2023”, the global CBCT market was valued at US$ 407.5 Mn in 2014 and is anticipated to expand at a CAGR of 10.0% from 2015 to 2023 to reach US$ 960.8 Mn by 2023.
Information related to diagnosis is vital for valid decision of a treatment plan in dentistry. Precise images lead to a better treatment plan and improved results. CBCT is an evolving technology suitable for dental images and maxillofacial structures. It can provide the most relevant clinical data compared to conventional imaging methods such as radiographs. The introduction of CBCT technology in dentistry has changed the diagnostic landscape rapidly allowing dental professionals to diagnose in three dimensions. CBCT systems are now preferred to conventional systems for advantages such as lower radiation dose to patients, smaller acquisition times for the resolution required in dentistry, and affordable cost option to medical CT, and improved resolution with more details.
Disorders prevalent among adult patients such as periodontal diseases, tooth loss, endodontically restored teeth, restored teeth and trauma sequelae, and coexisting with malocclusion are driving demand for various dentistry applications. Demand for orthodontic treatment in adults has increased significantly over the past few years with the need for detailed diagnosis. In orthodontics, CBCT helps in visualization of impacted teeth, identification of root resorption, ankylosis and dentoalveolar fracture, evaluation of height and bone volume, examination of temporomandibular joint and upper airway, accurate determination of bone-tooth inconsistencies in non-erupted teeth, and diagnosis of pathologies. Moreover, increasing accessibility of this technology helps dentists by providing three-dimensional representation of the maxillofacial skeleton with nominal distortion.
Based on application, the global cone beam computed tomography (CBCT) market has been segmented dental implants, orthodontics, oral surgery, endodontics, and general dental surgery. Geographically, the market has been analyzed for five regions: North America, Europe, Asia Pacific, Latin America, and Rest of the World. The CBCT market is driven by increasing demand for applications in dentistry across the globe. North America held the largest share of the CBCT market in 2014, followed by Europe. The largest market share of North America is attributed to increasing geriatric population and growing demand for advanced technology products for dental imaging in the U.S. According to statistics provided by the American Association of Oral and Maxillofacial Surgeons (2014), about 100,000 to 300,000 dental implants are placed each year. However, due to the industry’s failure to offer lower cost, conservative dentistry took a downturn during the recession.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=10508
Europe is a lucrative market for CBCT. Germany continues to lead the market in innovative invisible braces and demand for these orthodontic systems. Asia-Pacific was identified as the third largest market for CBCT in 2014. Demand has increased significantly in Asia due to rise in health care expenditures as well as disposable incomes of the population. Moreover, the market is driven by increase in population with oral diseases and disorders opting for advanced dental imaging techniques such as CBCT. The region is expected to register the fastest CAGR during the forecast period. Increasing awareness, disposable income, and government initiatives are driving the CBCT market in this region.
In Latin America, Mexico and Argentina are believed to be revenue pockets for the CBCT market. The market in Mexico and Argentina is expected to grow at a considerable rate. Population growth, increasing health spending, chronic disease incidence, and new technology acquisition, particularly diagnostic equipment in the public sector, are factors contributing to the growth of the market in Mexico.
Major players in this market are Cefla Group (Italy), Carestream Health (U.S.), Danaher Corporation (U.S.), QR s.r.l. (Newtom) (Italy), Planmeca OY (Finland), Prexion Inc. (U.S.), VATECH Global Co. Ltd. (South Korea), and Sirona Dental Systems (Germany).
Elafibranor Could be Just the Thing to Boost the Global Non-alcoholic Steatohepatitis Therapeutics Market
According to a new market report published by Transparency Market Research “Nonalcoholic Steatohepatitis Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2025”, the nonalcoholic steatohepatitis (NASH) therapeutics market is anticipated to expand at a CAGR of 10.7% from 2015 to 2025 to reach US$20.27 bn by 2025.
Nonalcoholic Steatohepatitis (NASH) is a syndrome that advances in patients who are not alcoholic; it causes liver damage that is histologically indistinguishable from alcoholic hepatitis. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware of their liver problem. However, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and no longer able to work properly. It develops most frequently in patients with at least one of the following risk factors as obesity, dyslipidemia, and glucose intolerance. Pathogenesis is not clearly understood but seems to be linked to insulin resistance. Most of the patients are asymptomatic. Laboratory outcomes include elevations in aminotransferase levels. Biopsy is essential to confirm the diagnosis. Treatment mainly focusses on elimination of causes and risk factors.
The prevalence of NASH and NAFLD is increasing across the globe but it is more in developed regions such as North America. Both NASH and NAFLD are becoming more common, perhaps because of the greater number of Americans with obesity. In the past few years, the rate of obesity has almost doubled in adults and tripled in children. Obesity also adds to diabetes and high blood cholesterol, which can further complicate the health of people suffering from NASH. Diabetes and high blood cholesterol are also becoming more common among Americans.
Currently, no specific therapies exist for NASH treatment. The most important recommendations given to persons with this disease are weight reduction (if overweight), following a balanced and healthy diet, increasing physical activity, avoiding alcohol and avoiding unnecessary medications.
The NASH market is segmented based on drug type which includes potential phase III candidates such as Obeticholic acid (OCA), Aramchol, Saroglitazar and Elafibranor. Moreover, the report enlists the candidates in Phase I and Phase II clinical trials. Based on the drug type, Elafibranor is expected to account for a major share of this market and the market for Elafibranor is expected to grow at the highest CAGR. This growth is majorly due to Elafibranor which is considered to be the most advanced drug in this category.
Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7691
Major players in this market are Astazeneca Plc (U.K.), Intercept Pharmaceuticals Inc. (U.S.), Galmed Pharmaceuticals Ltd. (Israel), GENFIT SA (France), Gilead Sciences, Inc. (U.S.), Zydus Cadila (India), Immuron Ltd. (Australia), Conatus Pharmaceuticals (U.S.), and Tobira Therapeutics, Inc. (U.S.).
Active Pharmaceutical Ingredient (API) refers to a substance or substance combination used in manufacturing a drug product. The active pharmaceutical ingredient market has been categorized by manufacturing process, API type, drug type, therapeutic area and geography. Manufacturing processes in the global API market include captive and contract manufacturing. The captive API manufacturing segment comprises the active pharmaceutical ingredients produced for internal consumption of a pharmaceutical company. Captive manufacturing accounted for the highest market share in 2014, however the share of this market segment is expected to witness a decline due high degree of competition from contract manufacturing and reduced profitability and thus increased preference for outsourcing API production over captive production. Outsourcing production helps pharmaceutical companies focus on their core business of developing new drug products. Contract manufacturing is being preferred because of its advantage in terms of capital and labor costs, access to advanced manufacturing technologies, and benefits from the global distribution network.
Obtain Report Details: http://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html
The global active pharmaceutical market is segmented into API types: synthetic chemical API and biological API. The synthetic chemical API segment held the largest share of more than 70% of active pharmaceutical market in 2014. This market segment has evolved in the past few years due to innovations in the methods of synthesizing chemical APIs, which improves their stability and potency. The large volume of the demand is an important reason for the larger share of synthetic chemical API segment. On the other hand, the biological API market segment is expected to have the highest growth rate of 8.1% during the forecast period of 2015-2023. Large pharmaceutical companies are scaling down their small molecule manufacturing facilities to focus on biologic drugs, thereby presenting greater opportunities for contract manufacturing companies. The overall cost of drug development program for biologics is less as compared to chemical APIs, primarily because of high success rates in the pipeline phase. This factor has attracted higher investments in the biologics and biosimilars market.
Drug types in the global API market include branded prescription drug, generic prescription drug and OTC drugs. The branded API segment accounted for the largest share of 76% in the global API market in 2014. The factors driving the branded prescription drugs include government initiatives that has lowered the copayment on generics while raising it on the branded drugs. The increasing demand for biological drugs and supportive policies of the European Union toward biosimilars is also one of the major driving factors to boost branded API market. Moreover, the generic prescription drugs segment is expected to grow at the highest rate of 7.3% during the forecast period. With the rising cost of healthcare, governments and payers are pushing for the increasing generics consumption over branded drugs, thus driving growth of the generic APIs market. Over-the-counter (drugs) are considered sufficiently safe and effective for use without prescriptions from health care professionals and hence would continue to grow at a steady rate during the forecast period.
Based on the therapeutic area, the global API market is segmented into various disorders such as cardiovascular, metabolic, disorders, oncology, musculoskeletal, non-steroidal anti-inflammatory drugs (NSAIDs), and others. The cardiovascular disorder segment held the largest share of global active pharmaceutical ingredient market during the forecast period. Cardiovascular, metabolic, and neurological disorders held a combined market share of over 50% in 2014 due to the rising geriatric population, increasing prevalence of cardiovascular diseases, diabetes and neurological disease globally. Whereas, the oncology segment is expected to grow at the highest rate of 8.2% during the forecast period owing to the rising prevalence of cancer. The significant growth observed in oncology API has helped companies to prefer specialized manufacturing plants for oncology drugs. The musculoskeletal disorders, NSAIDs and other therapeutics area is anticipated to grow at a steady rate during the forecast period of 2015 to 2023.
Geographically, North America dominated the active pharmaceutical ingredient market in 2014 with a share of 35.1% owing to factors such as higher consumption of API due to the presence of major pharmaceutical companies in this region. Biologics have become one of the top-selling drugs in North America. Thus, the expected market entry of biosimilars with flexible regulatory process would further boost the API market in North America. Japan, China, India and South Korea, the leading pharmaceutical hubs in Asia are majorly responsible for almost 30% of the total market share placing the region at the second position in the world. Major factors driving the API markets in China and India are the availability of low cost production facilities and labor cost. Other factors driving the market in the region include the tax incentives, rising government expenditure on health care and government plans to restructure the fragmented industry. Europe accounted for a market share of 21.6% in 2014. The governments of various countries in Europe have started supporting the manufacture of generic drugs post the financial crisis. Patent expirations of major blockbuster drugs in Europe would fuel the growth of the API market in the near future. Demand for generic drugs is increasing not only in developed countries, but also in developing and underdeveloped countries in South America and Africa. Brazil and South Africa are the important centers of pharmaceutical manufacturing in this regional segment. Factors boosting the growth of the market in developing regions are cost-efficient manufacturing, large number of patients, rising demand for generic drugs, and improvement in the healthcare infrastructure.
Teva Pharmaceutical Industries Ltd dominated active pharmaceutical ingredients market in 2014. Major factors attributed to its dominance are broad product portfolio and high market penetration. Zhejiang Medicine Co., Ltd. and Zhejiang NHU Co., Ltd secured the second market position in 2015. North China Pharmaceutical Group Corp. (NCPC) and Northeast Pharmaceutical Group Co., Ltd. held the third position in 2015. Other players in the active pharmaceutical ingredients market include Dr.Reddy’s Laboratories Limited, Sandoz (Novartis AG), Aurobindo Pharma Limited, Zhejiang Hisun Pharmaceutical Co., Ltd. and Zhejiang Huahai Pharmaceuticals Co., Ltd. and others.
According to a new market report published by Transparency Market Research “Tourniquet Market – (By Product – Tourniquet Systems, Tourniquet Cuffs; By Application – Arm Cuffs, Leg cuffs; By End-Users: Hospitals, Physician/Clinic, Non-institutional) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2015 – 2023” the global tourniquet market was valued at US$ 184.6 Mn in 2014 and is estimated to reach US$ 408.6 Mn by 2023 at a CAGR of 9.3% from 2015 to 2023.
Tourniquet device is a medical equipment which checks excessive bleeding from the affected body part by compressing the blood vessels and nerves. Tourniquet has been identified as one of the most reasonable options for controlling hemorrhages. User-friendly design, durability and low cost are some of the prime factors which increases the demand for tourniquet devices in hospitals and clinics. Increasing incidence of orthopedic injuries, military war injuries, and growing hospital admissions for surgeries are boosting the growth of the tourniquet market.
The global tourniquet market has been segmented into four major regions: North America, Europe, Asia Pacific, and Rest of the World, which are further categorized into various countries under each region. North America accounted for the largest market for the global tourniquet market in 2014. Dominance of North America has been attributed to increasing incidence of accidents which leads to serious limb injuries. The use of disposable tourniquet cuffs are on the rise in North America due to the product’s lower price and lesser risk of contamination. In addition, technological advancement associated with tourniquet system and cuffs would have a positive impact on the growth of the tourniquet market. North America comprises Canada and the U.S. North America was the largest market for tourniquet in 2014 primarily due to increasing incidence of road accidents leading to traumatic injuries and rapid introduction of advanced tourniquet devices. Furthermore, major players such as Zimmer Biomet and Stryker Corporation are based in North America. This is likely to boost market growth in the region.
Europe is the second largest market for global tourniquet market in 2014 due to increasing geriatric population undergoing surgeries, high awareness about available tourniquet cuffs, and favorable reimbursement policies. Germany has the largest market share of Europe tourniquet market due to improved health care infrastructure and a developed medical technology market. Factors attributed to the rapid growth of the tourniquet market in Europe are growing trend toward adoption of disposable tourniquet cuffs and increasing incidence of traffic-related injuries, sports injuries, and occupational injuries. The forecast reveals that countries in rest of the Europe would expand at the fastest CAGR during the forecast period.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=11627
Asia Pacific was the third largest market for tourniquet devices in 2014, and is anticipated to grow at the highest CAGR during the forecast period. Emerging markets in Asia Pacific hold immense growth potential due to factors such as rise in road accidents, increase in the prevalence of limb surgeries, growing health care expenditure, and improving health care infrastructure. For instance, according to the Central Bureau of Health Intelligence (India), the number of government hospitals in India has increased since year 2000 which is a strong reason for promising growth of the market in Asia Pacific region. Growth in medical tourism and market saturation from North America and Europe is one of the major factors for the increasing demand for tourniquet devices. China was the largest market for tourniquets in Asia Pacific. Presence of large population suffering from orthopedic injuries in countries such as Japan, China, and India adds to the large patient pool. This in turn increases the number of tourniquet cuffs used in surgeries.
The global tourniquet market exhibits intense competition among the existing players. The market is consolidated, characterized by the presence of few established companies. Major players operating in the global tourniquet market are Zimmer Biomet Holdings, Inc., Stryker Corporation, Delfi Medical Innovation, Inc., Hammarplast Medical AB, Pyng Medical Corporation, ulrich Medical, and VBM Medizintechnik GmbH.